WallStSmart

Anteris Technologies Global Corp. Common Stock (AVR)vsBoston Scientific Corp (BSX)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Boston Scientific Corp generates 936385% more annual revenue ($21.00B vs $2.24M). BSX leads profitability with a 17.5% profit margin vs 0.0%. BSX earns a higher WallStSmart Score of 72/100 (B).

AVR

Avoid

33

out of 100

Grade: F

Growth: 5.3Profit: 2.5Value: 5.0Quality: 6.5
Piotroski: 2/9Altman Z: -36.28

BSX

Strong Buy

72

out of 100

Grade: B

Growth: 7.3Profit: 7.0Value: 6.7Quality: 5.5
Piotroski: 5/9Altman Z: 1.78
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for AVR.

BSXOvervalued (-10.0%)

Margin of Safety

-10.0%

Fair Value

$39.07

Current Price

$42.98

$3.91 premium

UndervaluedFair: $39.07Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

AVR2 strengths · Avg: 10.0/10
Revenue GrowthGrowth
63.3%10/10

Revenue surging 63.3% year-over-year

Debt/EquityHealth
0.0110/10

Conservative balance sheet, low leverage

BSX6 strengths · Avg: 8.2/10
Market CapQuality
$62.29B9/10

Large-cap with strong market position

PEG RatioValuation
0.608/10

Growing faster than its price suggests

P/E RatioValuation
17.5x8/10

Attractively priced relative to earnings

Price/BookValuation
2.5x8/10

Reasonable price relative to book value

Operating MarginProfitability
22.9%8/10

Strong operational efficiency at 22.9%

Free Cash FlowQuality
$1.28B8/10

Generating 1.3B in free cash flow

Areas to Watch

AVR4 concerns · Avg: 3.3/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$813.78M3/10

Smaller company, higher risk/reward

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

BSX1 concerns · Avg: 4.0/10
Altman Z-ScoreHealth
1.784/10

Distress zone — elevated risk

Comparative Analysis Report

WallStSmart Research

Bull Case : AVR

The strongest argument for AVR centers on Revenue Growth, Debt/Equity. Revenue growth of 63.3% demonstrates continued momentum.

Bull Case : BSX

The strongest argument for BSX centers on Market Cap, PEG Ratio, P/E Ratio. Profitability is solid with margins at 17.5% and operating margin at 22.9%. PEG of 0.60 suggests the stock is reasonably priced for its growth.

Bear Case : AVR

The primary concerns for AVR are EPS Growth, Market Cap, Profit Margin.

Bear Case : BSX

The primary concerns for BSX are Altman Z-Score.

Key Dynamics to Monitor

AVR profiles as a hypergrowth stock while BSX is a mature play — different risk/reward profiles.

AVR carries more volatility with a beta of 0.73 — expect wider price swings.

AVR is growing revenue faster at 63.3% — sustainability is the question.

BSX generates stronger free cash flow (1.3B), providing more financial flexibility.

Bottom Line

BSX scores higher overall (72/100 vs 33/100), backed by strong 17.5% margins. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Anteris Technologies Global Corp. Common Stock

HEALTHCARE · MEDICAL DEVICES · USA

Anteris Technologies Global Corp. The company is headquartered in Toowong, Australia.

Boston Scientific Corp

HEALTHCARE · MEDICAL DEVICES · USA

Boston Scientific Corporation, doing business as Boston Scientific, is a manufacturer of medical devices used in interventional medical specialties, including interventional radiology, interventional cardiology, peripheral interventions, neuromodulation, neurovascular intervention, electrophysiology, cardiac surgery, vascular surgery, endoscopy, oncology, urology and gynecology.

Want to dig deeper into these stocks?